EQGen Biomedical

EQGen Biomedical is a clinical-stage biotechnology company based in Suzhou, China, dedicated to developing next-generation gene therapies for ocular and neurological diseases. The company utilizes a proprietary AAV vector platform to design treatments that offer long-term efficacy through a single dose, specifically targeting conditions like wet age-related macular degeneration (nAMD) and diabetic macular edema (DME). Its lead candidate, EG-001, has advanced into clinical trials, representing a significant milestone in its mission to address chronic diseases with high unmet medical needs. EQGen is supported by a team of experts in viral vector engineering and clinical development, and it has secured substantial funding from leading life science investors. The company maintains a dual presence in Suzhou and Shanghai to facilitate both research and manufacturing operations.